Sermorelin

Quick Answers About Sermorelin

• Is Sermorelin FDA approved?

  No. This profile records Sermorelin as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.

• What dose does The Peptide App Clinical Team recommend for Sermorelin?

  Dose: Unvalidated regimen: 0.3 mg SubQ once nightly on 5 days/week. Cycle: No clinically established cycle for this SubQ regimen.. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

• What research supports this Sermorelin guide?

  This guide links to 10 curated or current research sources.

• What are the side effects of Sermorelin?

  Reported side effects of Sermorelin include Injection site reactions, Flushing, Dizziness, and Headache. They are reported or occasional reactions, not a prediction of what any one person will experience.

• Is Sermorelin safe?

  Sermorelin has an editorial safety grade of B (Good Safety). Well tolerated with predictable side effects. Safer than exogenous HGH. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.

• What metabolites of sermorelin have been identified in laboratory studies?

  The only sermorelin metabolite named in these laboratory studies is sermorelin(3-29)-NH2, which was used in in vitro work with spiked urine. In that study, sermorelin(3-29)-NH2 was used as a reference material, together with parent peptides, to develop a liquid chromatography-tandem mass spectrometry method for detecting GHRH administration. A separate in vitro study investigated the metabolism of sermorelin in fortified urine, alongside tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex. That in vitro work identified nineteen major metabolites across the GHRH analogs, which were synthesized and characterized, but the facts do not state which of them come from sermorelin.

  • Advances in the detection of growth hormone releasing hormone synthetic analogs.

• Is sermorelin prohibited in sports under World Anti-Doping Agency rules?

  Sermorelin is a growth hormone-releasing hormone analogue that is included in the prohibited list of the World Antidoping Agency. WADA regulations state that the use of growth hormone-releasing hormones, which includes sermorelin, is prohibited in sports. WADA also prohibits administration of growth hormone releasing hormone and its synthetic analogs.

  • Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
  • Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
  • Advances in the detection of growth hormone releasing hormone synthetic analogs.

• How might sermorelin affect tumor cells according to pathway analyses?

  In observational human data, GO and KEGG pathway analyses suggested that sermorelin may inhibit tumor cell proliferation by cell cycle blocking. The same observational human study also reported that sermorelin was related to the immune system process and negatively regulated immune checkpoints and M0 macrophages.

  • A potentially effective drug for patients with recurrent glioma: sermorelin.

• How is sermorelin detected in urine samples?

  In laboratory work on human urine samples, sermorelin was analysed by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument, after immunopurification with magnetic beads. A refined sample preparation approach was developed for the target peptides, including sermorelin, in urine, combining an initial ultrafiltration step followed by solid-phase extraction. A sensitive liquid chromatography-tandem mass spectrometry method was developed to detect GHRH analogs and their metabolites, including the sermorelin metabolite sermorelin(3-29)-NH2, in spiked urine.

  • Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
  • Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
  • Advances in the detection of growth hormone releasing hormone synthetic analogs.

• Is there strong clinical efficacy evidence for sermorelin?

  A review states that current clinical efficacy data on growth hormone secretagogues, which include sermorelin, are largely lacking. The same review describes growth hormone secretagogues as a potential adjunctive therapy for some symptoms of hypogonadism, but notes that their clinical efficacy data largely remain lacking.

  • Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

• What detection limits have been reported for sermorelin in urine?

  In an in vitro study of urine, the method reached limits of detection for sermorelin between 5 and 25 pg/mL. The limits of identification were between 25 and 50 pg/mL, and these were established even without immuno-affinity purification steps. Other in vitro results report general limits for target peptides of 1 ng/ml or less, and for growth hormone-releasing hormone analogues a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL, but these are not specific to sermorelin.

  • An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
  • Advances in the detection of growth hormone releasing hormone synthetic analogs.
  • Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

• What did research find about sermorelin in recurrent glioma patients?

  In an observational study of human recurrent glioma patients, sermorelin was found to be suitable for those with high grade, IDH-wildtype and 1p/19q non-codeletion status. The Kaplan-Meier analysis in these patients showed that the benefit from sermorelin was independent of postoperative adjuvant treatment. The authors reported that recurrent glioma patients were sensitive to sermorelin, which was described as acting by inhibiting glioma cell proliferation and enhancing immune response.

  • A potentially effective drug for patients with recurrent glioma: sermorelin.

• What is sermorelin, also known as AC-8930?

  In the paper, sermorelin is written as GHRH(1-29)NH2, a GHRH analog that was sold under the brand Geref Diagnostic. The paper describes sermorelin (SERM) as a GH-releasing hormone analog and one of the GH secretagogues it investigated. A review names sermorelin as an example of a growth hormone-releasing hormone analogue among the agents most commonly encountered in clinical practice and online self-administration protocols.

  • Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency.
  • Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.
  • The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

• How stable is sermorelin in urine samples?

  In stability experiments on urine samples, sermorelin and its metabolite were found to degrade rapidly at temperatures above 4 °C and at pH values below 7. The study noted that proper handling of urine samples is important to avoid degradation of these peptide hormones, especially sermorelin and its metabolite. More generally, the analysis of GHRH and its analogs in urine was described as challenging because of their in vivo instability, rapid renal clearance, and low urinary concentrations.

  • An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
  • Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.